Cost-Effectiveness of Sacituzumab Tirumotecan vs Chemotherapy for EGFR- TKI–Resistant NSCLC: Evidence to Inform Drug Pricing in the U.S. and China
This economic evaluation demonstrates that while Sacituzumab tirumotecan is marginally cost-effective for EGFR-TKI–resistant NSCLC patients within the Chinese healthcare system, it is not cost-effective for U.S. patients under current pricing, necessitating significant price reductions to meet American willingness-to-pay thresholds.